Literature DB >> 28455089

A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies.

Miranda E Orr1, A Campbell Sullivan2, Bess Frost3.   

Abstract

There are currently no disease-modifying therapies for the treatment of tauopathies, a group of progressive neurodegenerative disorders that are pathologically defined by the presence of tau protein aggregates in the brain. Current challenges for the treatment of tauopathies include the inability to diagnose early and to confidently discriminate between distinct tauopathies in patients, alongside an incomplete understanding of the cellular mechanisms involved in pathogenic tau-induced neuronal death and dysfunction. In this review, we describe current diagnostic and therapeutic strategies, known drivers of pathogenic tau formation, recent contributions to our current mechanistic understanding of how pathogenic tau induces neuronal death, and potential diagnostic and therapeutic approaches.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; metabolic syndrome; neurodegeneration; tau; tauopathy; traumatic brain injury

Mesh:

Year:  2017        PMID: 28455089      PMCID: PMC5476494          DOI: 10.1016/j.tips.2017.03.011

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  110 in total

1.  Acute decrease in alkaline phosphatase after brain injury: A potential mechanism for tauopathy.

Authors:  Peethambaran Arun; Samuel Oguntayo; Stephen Van Albert; Irene Gist; Ying Wang; Madhusoodana P Nambiar; Joseph B Long
Journal:  Neurosci Lett       Date:  2015-10-19       Impact factor: 3.046

2.  Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.

Authors:  Jiaping Gu; Erin E Congdon; Einar M Sigurdsson
Journal:  J Biol Chem       Date:  2013-10-02       Impact factor: 5.157

3.  Depletion of microglia and inhibition of exosome synthesis halt tau propagation.

Authors:  Hirohide Asai; Seiko Ikezu; Satoshi Tsunoda; Maria Medalla; Jennifer Luebke; Tarik Haydar; Benjamin Wolozin; Oleg Butovsky; Sebastian Kügler; Tsuneya Ikezu
Journal:  Nat Neurosci       Date:  2015-10-05       Impact factor: 24.884

Review 4.  Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease - challenges and perspectives.

Authors:  Maria Cristina Polidori; Gereon Nelles
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice.

Authors:  De-Lin Ma; Fu-Qiong Chen; Wei-Jie Xu; Wen-Zhu Yue; Gang Yuan; Yan Yang
Journal:  J Neurochem       Date:  2015-08-11       Impact factor: 5.372

6.  Wogonin increases β-amyloid clearance and inhibits tau phosphorylation via inhibition of mammalian target of rapamycin: potential drug to treat Alzheimer's disease.

Authors:  Yuyou Zhu; Juan Wang
Journal:  Neurol Sci       Date:  2015-01-18       Impact factor: 3.307

7.  New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.

Authors:  D P Hanger; J C Betts; T L Loviny; W P Blackstock; B H Anderton
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

8.  Effects of alpha-tocopherol on an animal model of tauopathies.

Authors:  Hanae Nakashima; Takeshi Ishihara; Osamu Yokota; Seishi Terada; John Q Trojanowski; Virginia M-Y Lee; Shigetoshi Kuroda
Journal:  Free Radic Biol Med       Date:  2004-07-15       Impact factor: 7.376

9.  Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3 -dependent phosphorylation of Tau.

Authors:  Volker Meske; Frank Albert; Thomas Georg Ohm
Journal:  J Biol Chem       Date:  2007-10-30       Impact factor: 5.157

10.  Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy.

Authors:  D L Dickstein; M Y Pullman; C Fernandez; J A Short; L Kostakoglu; K Knesaurek; L Soleimani; B D Jordan; W A Gordon; K Dams-O'Connor; B N Delman; E Wong; C Y Tang; S T DeKosky; J R Stone; R C Cantu; M Sano; P R Hof; S Gandy
Journal:  Transl Psychiatry       Date:  2016-09-27       Impact factor: 6.222

View more
  55 in total

1.  Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease.

Authors:  Nicolai Franzmeier; Anna Rubinski; Julia Neitzel; Yeshin Kim; Alexander Damm; Duk L Na; Hee Jin Kim; Chul Hyoung Lyoo; Hana Cho; Sofia Finsterwalder; Marco Duering; Sang Won Seo; Michael Ewers
Journal:  Brain       Date:  2019-04-01       Impact factor: 13.501

2.  Epilepsy and Alzheimer's Disease: Ubiquitous Entities Subject to the Same Cosmic Forces but on Different Astral Planes.

Authors:  Cynthia L Harden
Journal:  Epilepsy Curr       Date:  2018 Sep-Oct       Impact factor: 7.500

3.  Importance of Treatment Status in Links Between Type 2 Diabetes and Alzheimer's Disease.

Authors:  Elissa C McIntosh; Daniel A Nation
Journal:  Diabetes Care       Date:  2019-03-04       Impact factor: 19.112

Review 4.  Amyloidogenesis of Tau protein.

Authors:  Bartosz Nizynski; Wojciech Dzwolak; Krzysztof Nieznanski
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

Review 5.  PART 3 Bypassing TBI: Metabolic Surgery and the Link Between Obesity and Traumatic Brain Injury-a Review.

Authors:  T W McGlennon; J N Buchwald; Walter J Pories; Fang Yu; Arthur Roberts; Eric P Ahnfeldt; Rukmini Menon; Henry Buchwald
Journal:  Obes Surg       Date:  2021-01-04       Impact factor: 4.129

Review 6.  Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease.

Authors:  Tara E Tracy; Li Gan
Journal:  Curr Opin Neurobiol       Date:  2018-05-10       Impact factor: 6.627

Review 7.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

8.  Suppression of tau propagation using an inhibitor that targets the DK-switch of nSMase2.

Authors:  Tina Bilousova; Chris Elias; Emily Miyoshi; Mohammad Parvez Alam; Chunni Zhu; Jesus Campagna; Kanagasabai Vadivel; Barbara Jagodzinska; Karen Hoppens Gylys; Varghese John
Journal:  Biochem Biophys Res Commun       Date:  2018-04-09       Impact factor: 3.575

Review 9.  Development of disease-modifying drugs for frontotemporal dementia spectrum disorders.

Authors:  Francesco Panza; Bruno P Imbimbo; Madia Lozupone; Davide Seripa; Antonio Daniele; Mark Watling; Gianluigi Giannelli
Journal:  Nat Rev Neurol       Date:  2020-03-23       Impact factor: 42.937

Review 10.  Pathological Continuum From the Rise in Pulse Pressure to Impaired Neurovascular Coupling and Cognitive Decline.

Authors:  Olivia de Montgolfier; Nathalie Thorin-Trescases; Eric Thorin
Journal:  Am J Hypertens       Date:  2020-04-29       Impact factor: 2.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.